ImmunityBio (NASDAQ:IBRX) Shares Gap Down – Time to Sell?

ImmunityBio, Inc. (NASDAQ:IBRX) shares gapped down before the market opened on Wednesday . The stock had previously closed at $6.48, but opened at $6.27. ImmunityBio shares last traded at $6.1450, with a volume of 36,049,692 shares traded.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA outlined a clear resubmission path for ANKTIVA (nogapendekin alfa inbakicept) in BCG?unresponsive papillary NMIBC; ImmunityBio says it will submit additional information within ~30 days after the Type B end?of?phase meeting — a concrete regulatory route that materially reduces near?term binary risk. ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA®
• Positive Sentiment: Market reaction: multiple outlets report the stock jumped sharply (mid?January moves of ~15–20%) after the FDA meeting news, reflecting investor belief that a resubmission could unlock labeled use in an oncology market — the surge has increased liquidity and attention on the ticker. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Analyst/upside notes: HC Wainwright raised long?range FY2030 EPS estimates materially (A. Maldonado: $0.68 FY2030), and at least one boutique shop reaffirmed a buy with a high $24 price target — these calls support a bullish narrative and can lift sentiment among growth investors.
• Neutral Sentiment: Momentum: coverage highlights the stock hitting fresh highs and an extended multi?day rally; that’s bullish signal?wise but increases the chance of short?term pullbacks as traders take profits. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Bull case discussion: independent bull analyses and commentary outline multiple upside scenarios tied to ANKTIVA label expansion and other pipeline assets — useful for longer?term thesis but dependent on regulatory and commercial execution. ImmunityBio, Inc. (IBRX): A Bull Case Theory
• Negative Sentiment: Risk/valuation and sell?side caution: some sector pieces flagged IBRX among names to avoid given extreme momentum and event?driven volatility; the company still faces clinical, regulatory and commercialization risk, and the recent run has left the share price stretched versus fundamentals. Top 3 Health Care Stocks You May Want To Dump In January

Analysts Set New Price Targets

IBRX has been the topic of a number of analyst reports. Piper Sandler lifted their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $24.00 target price on shares of ImmunityBio in a research note on Tuesday. Finally, Jefferies Financial Group boosted their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, ImmunityBio currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

ImmunityBio Stock Performance

The stock has a market capitalization of $6.76 billion, a P/E ratio of -16.79 and a beta of 0.03. The business has a 50 day simple moving average of $2.44 and a 200-day simple moving average of $2.49.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to the consensus estimate of $31.88 million. Equities research analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On ImmunityBio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC purchased a new stake in ImmunityBio during the second quarter valued at about $20,497,000. Heights Capital Management Inc. purchased a new position in ImmunityBio during the 3rd quarter worth approximately $16,152,000. Vanguard Group Inc. lifted its holdings in shares of ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after purchasing an additional 5,837,898 shares in the last quarter. AlphaCore Capital LLC acquired a new position in ImmunityBio during the second quarter valued at $7,854,000. Finally, Woodline Partners LP lifted its stake in ImmunityBio by 53.7% in the 3rd quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock worth $13,032,000 after acquiring an additional 1,851,854 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.